Humanin
Never given to people in a published study.
A small peptide encoded in that protects cells from stress in the lab. In one small study, children of centenarians had more of it in their blood than other people their age. Nobody has published a study giving it to people. A , also called HN and HNG (a stronger lab variant).
What the evidence shows
Side effects and risks
Who should avoid it: Treat it as untested.
How it works
- Where it acts
- Receptors on the cell surface that trigger survival signals.
- What it changes
- It protects cells from stress in lab studies.
- What people notice
- It has never been given to people in a published study.
How it has been given in studies
No human dose exists.
Getting it in the United States
The legal route for Humanin
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Too few reports to summarize.
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Said his team's 2020 work was the first to show humanin can extend lifespan in animals and argued it could become a treatment target. The human data were small and correlational.
Source: USC News, 2020-06
Pinchas CohenWebsiteRecommends
Money: Consultant and stockholder of CohBar
Photo source: eurekalert.org
Led the 2020 study and noted a trade-off: animals engineered for more humanin lived longer but had fewer offspring. He framed humanin as an ancient signal linking reproduction and lifespan.
Source: Neuroscience News, 2020-06
Kelvin YenWebsiteMixed view
Photo source: today.usc.edu
Co-authored the finding that 18 children of centenarians had higher humanin levels than 19 controls. The work shows an association and does not test giving the peptide to people.
Source: Aging journal record, 2020-06
Nir BarzilaiWebsiteRecommends
Money: Consultant and stockholder of CohBar
Photo source: longevitybiotech.org
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Many peptides have names that sound like Yiddish words. Here's why.
Asaf Elia-Shalev
USC's Pinchas Cohen on how his mitochondria-derived peptides were named, and his warning that gray-market peptide injections need physician oversight and trials.
Humanin-family researcher cautions against gray-market peptide use
When options run out
Uses people turn to when standard treatment has failed.
Alzheimer's and MELAS research interest
- Who
- Families facing dementia or mitochondrial disease who read that patients have low humanin levels and look for a supplement.
- Evidence
- Only observational links and mouse studies with an analog. A gene variant tied to lower humanin tracked with older cognitive age. No human treatment trial.
Source: Scientific Reports, 2018
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does humanin slow aging?
There is no human evidence. A lab variant improved body composition in old mice but did not extend their lives.
Has humanin been tested in people?
No. Nobody has published a study giving it to people. In one small study, children of centenarians had more of it in their blood than other people their age.
Is humanin safe?
There are no human safety data. Mice engineered to make extra humanin had much smaller litters.
Is humanin legal?
In the US it is a research chemical and has never been nominated for pharmacy compounding.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem